Tested Applications
| Positive WB detected in | HEK-293 cells, HeLa cells, LNCaP cells, U2OS cells |
| Positive IP detected in | HuH-7 cells |
| Positive IHC detected in | human lung cancer tissue, human skin cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HEK-293 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:16000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:200-1:800 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
30052-1-AP targets B7-H3/CD276 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Recombinant protein Predict reactive species |
| Full Name | CD276 molecule |
| Calculated Molecular Weight | 57 kDa |
| Observed Molecular Weight | 95-100 kDa |
| GenBank Accession Number | NM_001024736 |
| Gene Symbol | CD276 |
| Gene ID (NCBI) | 80381 |
| RRID | AB_3086220 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q5ZPR3 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
B7-H3 (CD276) is a type I transmembrane protein expressed on many tissues and cell types. B7-H3 is a 100-kDa glycoprotein that belongs to the B7 immunoregulatory family and participates in the regulation of T-cell-mediated immune response probably by functioning as both a T cell costimulator and coinhibitor (PMID: 25567370; 20696859). Overexpressed on a wide range of human solid cancers, B7-H3 has been implicated in cancer progression and metastasis and becomes an attractive target for cancer immunotherapy (PMID: 27208063).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for B7-H3/CD276 antibody 30052-1-AP | Download protocol |
| IHC protocol for B7-H3/CD276 antibody 30052-1-AP | Download protocol |
| IP protocol for B7-H3/CD276 antibody 30052-1-AP | Download protocol |
| WB protocol for B7-H3/CD276 antibody 30052-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The B7-H3/CD276 Polyclonal antibody (Cat# 30052-1-AP) has a total of 1 citation. It appears in the journal Oncology Research (Impact Factor 4.6), published in December 2024. The cited study investigated how Hsa-miR-214-3p inhibits breast cancer cell growth and improves the tumor immune microenvironment by downregulating B7H3, placing the research field in oncology, specifically breast cancer biology and tumor immunology. The antibody was used for Western blot analysis in human samples.
| Species | Application | Title |
|---|---|---|
Oncol Res Hsa-miR-214-3p inhibits breast cancer cell growth and improves the tumor immune microenvironment by downregulating B7H3 |
